H. Read

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial

S. Eichner, P. Rutgeerts, G. D'Haens, 2016, Journal of Crohn's & colitis.

Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect of CYP2D6*10/*10 Genotype in Healthy Japanese Men

K. Desante, J. Azuma, J. Sauer, 2012, Journal of clinical pharmacology.

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

J. McCracken, Shuyu Zhang, D. Michelson, 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

P. Rutgeerts, S. Hanauer, G. Van Assche, 2018, Alimentary pharmacology & therapeutics.

Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome

J. Gillespie, B. Ring, S. Wrighton, 2004, Journal of Pharmacology and Experimental Therapeutics.

Hepatic Events Associated with Atomoxetine Treatment for Attention-Deficit Hyperactivity Disorder

J. Wernicke, A. Allen, Shuyu Zhang, 2008, Drug safety.

Hemodynamic Effects of Acute Administration of Atomoxetine and Methylphenidate

R. Kelly, S. Lowe, S. Wise, 2005, Journal of clinical pharmacology.

Pharmaceutical risk management: a call to arms for pharmacoepidemiology

D. L. Hyslop, H. Read, D. Masica, 2002, Pharmacoepidemiology and drug safety.